Keynote review: phosphodiesterase-4 as a therapeutic target
about
The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injuryCyclic nucleotide specific phosphodiesterases of Leishmania major.New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilastInteraction with receptor for activated C-kinase 1 (RACK1) sensitizes the phosphodiesterase PDE4D5 towards hydrolysis of cAMP and activation by protein kinase CMdm2 directs the ubiquitination of beta-arrestin-sequestered cAMP phosphodiesterase-4D5Promising new treatments for psoriasisRolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.Treating brain tumors with PDE4 inhibitorsBeta-adrenoceptor stimulation potentiates insulin-stimulated PKB phosphorylation in rat cardiomyocytes via cAMP and PKAPhosphodiesterase 4 inhibition enhances the dopamine D1 receptor/PKA/DARPP-32 signaling cascade in frontal cortex.Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferationTreating lung inflammation with agonists of the adenosine A2A receptor: promises, problems and potential solutionsSleep deprivation impairs cAMP signalling in the hippocampusPDE4 inhibitors: current statusA short review on structure and role of cyclic-3',5'-adenosine monophosphate-specific phosphodiesterase 4 as a treatment toolSelective Phosphodiesterase Inhibitors for Psoriasis: Focus on ApremilastThe impact of sleep deprivation on neuronal and glial signaling pathways important for memory and synaptic plasticityThe role of ventral striatal cAMP signaling in stress-induced behaviors.Efficacy of selective PDE4D negative allosteric modulators in the object retrieval task in female cynomolgus monkeys (Macaca fascicularis)Synthesis, Pharmacological Profile and Docking Studies of New Sulfonamides Designed as Phosphodiesterase-4 InhibitorsCrystal Structure and Computational Analyses Provide Insights into the Catalytic Mechanism of 2,4-Diacetylphloroglucinol Hydrolase PhlG from Pseudomonas fluorescensStructures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitorsCrystal structure of the Leishmania major phosphodiesterase LmjPDEB1 and insight into the design of the parasite-selective inhibitorsConformational Variations of Both Phosphodiesterase-5 and Inhibitors Provide the Structural Basis for the Physiological Effects of Vardenafil and SildenafilAn insight into the pharmacophores of phosphodiesterase-5 inhibitors from synthetic and crystal structural studiesKinetic and Structural Studies of Phosphodiesterase-8A and Implication on the Inhibitor Selectivity † ‡Synthesis, Structural Analysis, and Biological Evaluation of Thioxoquinazoline Derivatives as Phosphodiesterase 7 InhibitorsConformation Changes, N-terminal Involvement, and cGMP Signal Relay in the Phosphodiesterase-5 GAF DomainStructural Asymmetry of Phosphodiesterase-9, Potential Protonation of a Glutamic Acid, and Role of the Invariant GlutamineStructure-Based Discovery of Highly Selective Phosphodiesterase-9A Inhibitors and Implications for Inhibitor DesignFragment-Based Screening for Inhibitors of PDE4A Using Enthalpy Arrays and X-ray CrystallographyStereoselective synthesis of novel pyrazole derivatives using tert-butansulfonamide as a chiral auxiliaryDiscovery of triazines as selective PDE4B versus PDE4D inhibitorsManaging patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasisHuman phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progressionPDE 7 inhibitors: new potential drugs for the therapy of spinal cord injuryEnhanced expression of ADCY1 underlies aberrant neuronal signalling and behaviour in a syndromic autism model.Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3.Developmental etiology for neuroanatomical and cognitive deficits in mice overexpressing Galphas, a G-protein subunit genetically linked to schizophrenia.
P2860
Q21089854-B1083BDF-BA0D-408B-A3CF-855FDBD17A5EQ21093362-85A41F0A-332D-46A3-B9C3-2732E4248808Q22305855-8A60AA57-12A9-42C3-8065-AE1950F88F33Q24298838-5B658DA5-4F7D-4D18-BEB7-88F24DF7BFBEQ24316484-35935DF9-1250-4D52-BDAE-451706F81754Q24598008-5AF16868-9BEE-47B2-8B0F-43F9271FCB6FQ24609188-63EAF29D-4555-477A-9CD5-B968EAE09162Q24628917-1C164D27-FDF3-4CC8-B1D8-BC73CBE2F5F3Q24632097-D8D57CBF-1BE3-411E-8F13-121D5AC6101FQ24633622-B28B18B1-2E2F-4F31-A4AF-3689936E405FQ24634179-935EA2A4-F242-4C50-A7F0-64E9BFB76B72Q24641873-01D1CCF7-6D29-48E1-A596-24E775AC4D1EQ24644038-B0F6A1AE-B505-4D5A-9484-645C95105F22Q24650477-0BDBE4D9-31D0-480E-BBD5-54F750520C0AQ24651926-9B65FC40-267E-407D-A115-77FEB4766C62Q26773564-29F1313B-B77C-4ABB-83B5-32295C300D48Q26781755-0A3AB1C9-5070-4141-9ED1-772115D23DF8Q26852570-0FC43080-31F4-4245-B402-4E7ADEE9AED0Q27312156-0E9D4F35-E2D8-47CC-9E59-CCD65E9D8D2BQ27319287-48961B06-C524-4A1F-A6A6-75A3CEC58A65Q27322207-4D10CF51-BEAB-45D9-8F24-9F35391AEFA3Q27646614-4633DBCA-116A-4B56-9C17-47F8D89AEB62Q27647620-6A16B932-9B2A-4269-95D7-10FFC61F0481Q27648821-636BCE35-FCD1-4FBD-8FCC-4E5DC04DC925Q27648887-CC340978-DFB4-4DEB-A185-8E1BAF98A7B8Q27650091-B18BECE5-B59D-4059-864A-A08E7C3953A0Q27652751-D64B4583-9E10-4860-BD68-F35F7ED25D3FQ27654567-27ABB092-3BBF-4D2F-9746-65B9BE43E845Q27664639-B1554E68-B715-4781-AD44-9D7470F5B276Q27667496-5643BEA6-5869-4F16-9548-DB4829184C9CQ27673292-2E60B38E-A2EF-4B04-B780-AD9FBD11E43CQ27676592-9F689E97-DB41-42F1-B98F-6E117BA1D6FFQ27677514-7F1B0725-1148-4C4C-9641-00699152D11BQ27684573-95BBEE71-3708-4B24-809D-CE2FA8C9C620Q27693878-5604D8DD-645E-42A6-A3F6-235FC157285DQ28269917-EE0DBDAA-CE39-4036-AFB4-0EE1519C3F60Q28477025-240FAB77-DFF7-4812-A62F-F7AD4EE722F1Q30362378-3A783D92-50BB-4B54-B3CA-A337D6106BDEQ30408186-39E329DA-4C9A-4F88-A0CA-5BA638BDDF5AQ30469285-4F4EA1DE-8E09-4565-B381-1B7E8BCD9999
P2860
Keynote review: phosphodiesterase-4 as a therapeutic target
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Keynote review: phosphodiesterase-4 as a therapeutic target
@ast
Keynote review: phosphodiesterase-4 as a therapeutic target
@en
Keynote review: phosphodiesterase-4 as a therapeutic target
@nl
type
label
Keynote review: phosphodiesterase-4 as a therapeutic target
@ast
Keynote review: phosphodiesterase-4 as a therapeutic target
@en
Keynote review: phosphodiesterase-4 as a therapeutic target
@nl
prefLabel
Keynote review: phosphodiesterase-4 as a therapeutic target
@ast
Keynote review: phosphodiesterase-4 as a therapeutic target
@en
Keynote review: phosphodiesterase-4 as a therapeutic target
@nl
P3181
P1433
P1476
Keynote review: phosphodiesterase-4 as a therapeutic target
@en
P2093
Kam Y J Zhang
Peter Schafer
P304
P3181
P356
10.1016/S1359-6446(05)03622-6
P407
P577
2005-11-15T00:00:00Z